Current position

Ray Dalio’s Gsk Plc (GSK) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

Bridgewater Associates, LPVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ3 2022Earliest verified positive filing snapshot
Latest statusCurrent positionBased on the latest supported relationship state
Peak shares2.25MHighest verified quarter-end share count
Quarters reported16Verified quarters with shares above zero
What happened?

Bridgewater Associates, LP first reported Gsk Plc in Q3 2022. The reported position was increased and reduced across later filings. Bridgewater Associates, LP currently reports 504.17K shares. The latest verified filing showed: Sold 27.8% of the position.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q2 2026
Sold 27.8% of the position−194.50K shares · 504.17K shares remained
Filing context

Quarter-end price $52.42 · Estimated holding basis $36.71

Q1 2026
Sold 50.7% of the position−717.86K shares · 698.67K shares remained
Filing context

Quarter-end price $55.19 · Estimated holding basis $36.71

Q4 2025
Bought 1.1% more+14.77K shares · 1.42M shares reported after the change
Filing context

Quarter-end price $49.04 · Estimated holding basis $36.71

Q3 2025
Bought 4.3% more+57.71K shares · 1.40M shares reported after the change
Filing context

Quarter-end price $43.16 · Estimated holding basis $36.58

Q2 2025
Bought 11.7% more+140.95K shares · 1.34M shares reported after the change
Filing context

Quarter-end price $38.40 · Estimated holding basis $36.30

Q1 2025
Sold 46.5% of the position−1.04M shares · 1.20M shares remained
Filing context

Quarter-end price $38.74 · Estimated holding basis $36.05

Portfolio importance

How important is Gsk Plc in Bridgewater Associates, LP’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Current portfolio weight0.1%Q2 2026
Current rank#157of 997 reported positions
Peak portfolio weight0.3%Q4 2024
Best historical rank#54Q4 2024
At peak importanceQ4 2024
GSK
0.3%
Largest holding
22.1%
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$50.292026-09-16

Market context only; not an investor transaction price.

Latest filing quarter-end price$52.42Q2 2026

Derived from validated reported value and shares where supported.

Estimated holding basis$36.71Historical reference — not actual purchase price

Calculated from supported filing history.

Latest verified investor filingQ2 2026 · filed 2026-08-14
Open SEC filing ↗

This tracker follows Bridgewater Associates, LP’s Form 13F disclosures, not Ray Dalio’s personal brokerage account. Form 13F reports quarter-end positions later and does not reveal exact trade dates or execution prices.